Sergio Ghirardo, Giorgio Cozzi, Giovanna Tonin, Francesco Maria Risso, Laura Dotta, Alessandro Zago, Daniela Lupia, Paola Cogo, Nicola Ullmann, Antonella Coretti, Raffaele Badolato, Alessandro Amaddeo, Egidio Barbi, Renato Cutrera, Ghirardo, Sergio, Cozzi, Giorgio, Tonin, Giovanna, Risso, Francesco Maria, Dotta, Laura, Zago, Alessandro, Lupia, Daniela, Cogo, Paola, Ullmann, Nicola, Coretti, Antonella, Badolato, Raffaele, Amaddeo, Alessandro, Barbi, Egidio, and Cutrera, Renato
After the SARS-CoV-2 pandemic, we noticed a marked increase in high-flow nasal cannula use for bronchiolitis. This study aims to report the percentage of children treated with high-flow nasal cannula (HFNC) in various seasons. The secondary outcomes were admissions for bronchiolitis, virological results, hospital burden, and NICU/PICU need. We conducted a retrospective study in four Italian hospitals, examining the medical records of all infants (p p Conclusion: This study shows a marked increase in respiratory support and intensive care admissions this last winter. While these severity indexes were all driven by medical choices, more reliable indexes such as intubation rate and length of stay did not change. Therefore, we suggest that there is a more aggressive treatment attitude rather than a more severe disease. What is Known:• COVID-19 pandemic deeply impacted bronchiolitis epidemiology, reducing hospitalizations to onetenth. In the 2021-2022 winter, bronchiolitis resurged to pre-pandemic numbers in Europe. What is New:• Bronchiolitis hospitalization rose much faster in the 2021-2022 winter period, peaking at a higher level. Respiratory supports and high-flow nasal cannula increased significantly compared to the pre-pandemic era.